Plasmonic Nanoparticles for Selective Phototherapy Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cell proliferation disorders, such as cancer, face challenges in differentiating between normal and target cells, often resulting in non-selective damage to healthy cells and requiring invasive procedures to reach deep tissues, limiting their effectiveness and increasing side effects.
Innovation Solution
The method employs plasmonics materials and energy cascades to activate pharmaceutical agents in situ, using initiation energies like UV-A or X-rays to enhance electromagnetic fields, allowing for precise treatment of cell proliferation disorders without invasive techniques, by leveraging plasmonic nanostructures to amplify and direct energy for targeted cellular changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional phototherapy is used to treat cell proliferation disorders, then treatment can be applied, but the ability to differentiate between normal and target cells is poor, resulting in non-selective damage to healthy cells
Solution Approach 1:
The patent introduces plasmonic nanoparticles as intermediary agents that mediate between the light source and the photosensitizer. These nanoparticles enhance the local electromagnetic field and generate hot electrons that selectively activate the photosensitizer at the nanoparticle surface, enabling precise targeting of malignant cells while sparing healthy tissue.
Solution Approach 2:
The patent applies local quality enhancement by concentrating the photothermal and photochemical effects at the specific location where plasmonic nanoparticles are accumulated. The localized surface plasmon resonance creates highly concentrated energy delivery at the nanoparticle surface, achieving selective activation of photosensitizers only in the tumor region.
2Productivity
If invasive procedures are used to reach deep tissues for treatment, then treatment effectiveness can be improved, but patient comfort and treatment accessibility are reduced
Solution Approach 1:
The patent replaces invasive mechanical delivery methods with non-invasive optical activation. By using light sources that can penetrate tissue (such as lasers or LEDs) to activate the plasmonic nanoparticle-photosensitizer system, the treatment eliminates the need for surgical insertion or invasive procedures while maintaining deep tissue accessibility.
Solution Approach 2:
The plasmonic nanoparticles serve as intermediaries that are delivered to the tumor site through non-invasive means (such as intravenous injection) and then activated by external light sources. This intermediary system bridges the gap between non-invasive delivery and effective deep tissue treatment.
3Reliability
If conventional phototherapy is used, then treatment can be administered, but the selectivity for targeted cells is limited and side effects increase
Solution Approach 1:
The plasmonic nanoparticles act as selective intermediaries that enhance the phototherapeutic effect only where they are accumulated (in malignant cells). The combination of plasmonic field enhancement and hot electron generation creates a highly selective activation mechanism that minimizes off-target effects and reduces side effects.
Solution Approach 2:
The patent changes the energy delivery parameters by utilizing surface plasmon resonance frequencies that are highly sensitive to the local environment. This allows precise control over the activation threshold and energy delivery rate, enabling selective activation of photosensitizers in tumor cells while leaving healthy cells unaffected.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables non-invasive, high-selectivity treatment of cell proliferation disorders, reducing side effects and enabling the treatment of deep-seated tumors and non-blood related disorders by precisely activating pharmaceutical agents within the body, promoting targeted cellular changes and immune responses.
Implementation Method 1
plasmonics materials and energy cascades to activate pharmaceutical agents in situ, using initiation energies like UV-A or X-rays to enhance electromagnetic fields, allowing for precise treatment of cell proliferation disorders
Implementation Method 2
The method employs plasmonics materials and energy cascades to activate pharmaceutical agents in situ
Implementation Method 3
applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics agent enhances the applied initiation energy, such that the enhanced initiation energy activates the activatable agent in situ
Data Source
AI summary
The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.